Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Atea Pharmaceuticals Inc. - news published 180 - readings 3.368

BACK

Atea Pharmaceuticals Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2025 (March 31, 2025) Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jur ...

01.04.2025

Atea Pharmaceuticals Inc.

Material Event (Form 8-K)

Item 8.01 Other Events. On March 31, 2025, Atea Pharmaceuticals, Inc. (the "Company" or "Atea") received notice from Driver Opportunity Partners III withdrawing its prior notice that it intended to nominate J. Abbott R. Cooper to stand for election to the Company's Board of Directors at the Company's 2025 Annual Meeting of Stockholders (the "2025 Ann ...

01.04.2025

Atea Pharmaceuticals Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ?? ...

26.03.2025

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Atea Pharmaceuticals Inc. published this content on March 26, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 26, 2025 at 18:14:26.331 .

26.03.2025

Atea Pharmaceuticals Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2025 (March 21, 2025) Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other ju ...

24.03.2025

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Issues Statement Regarding Director Nominations (Form 8-K)

Atea Pharmaceuticals Issues Statement Regarding Director Nominations No Shareholder Action is Required at this Time BOSTON, March 21, 2025 (5:54 PM ET) (GLOBE NEWSWIRE) - Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today ...

24.03.2025

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

No Shareholder Action is Required at this Time BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today confirmed receipt of a notice from Bradley L. Radoff that he intends to nominate ...

21.03.2025

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Atea Pharmaceuticals Inc. published this content on March 19, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 19, 2025 at 11:10:24.540 .

19.03.2025

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Atea Pharmaceuticals Inc. published this content on March 06, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 06, 2025 at 21:26:48.645 .

06.03.2025

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 6, 2025 PDF Version Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March 06, 2025 ...

06.03.2025

Atea Pharmaceuticals Inc.

Fourth Quarter 2024 Financial Results Conference Call Presentation

Q4 and Full Year 2024 Financial and Business Update March 6, 2025 Q4 2024 and Recent Q1 2025 Updates HCV Program Update Robust Phase 2 results for regimen of bemnifosbuvir and ruzasvir announced in Dec. 2024 -- regimen, if approved, supports opportunity to disrupt global HCV market of ~$3B in annual net sales Successful End-of-Phase 2 meeting with FDA conducted in Jan. 2025 -- ...

06.03.2025

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Atea Pharmaceuticals Inc. published this content on February 27, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 27, 2025 at 12:30:52.000 .

27.02.2025

Atea Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

25.02.2025

Atea Pharmaceuticals Inc.

Initial Statement of Beneficial Ownership (Form 3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 (Print or Type Responses) 1. Nam ...

25.02.2025

Atea Pharmaceuticals Inc.

Management Change/Compensation (Form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 20, 2025 (the "Effective Date"), the Board of Directors (the "Board") of Atea Pharmaceuticals, Inc. (the "Company") elected Arthur Kirsch as a Class I director of the Company, e ...

24.02.2025

Atea Pharmaceuticals Inc. - news published 180 - readings 3.368

Atea Pharmaceuticals Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)

Atea Pharmaceuticals Inc.

Material Event (Form 8-K)

Atea Pharmaceuticals Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

Atea Pharmaceuticals Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Issues Statement Regarding Director Nominations (Form 8-K)

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals Inc.

Fourth Quarter 2024 Financial Results Conference Call Presentation

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Atea Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Atea Pharmaceuticals Inc.

Initial Statement of Beneficial Ownership (Form 3)

Atea Pharmaceuticals Inc.

Management Change/Compensation (Form 8-K)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member